BeOne Medicines (BEIGF) Total Debt Growth (3y) (2018 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Total Debt Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.48 Bn | 625.73 Bn | 17.26 Bn | 1.95% |
| 2 | AbbVie | 442.74 Bn | 436.17 Bn | 12.70 Bn | 5.09% |
| 3 | Merck | 366.39 Bn | 359.25 Bn | 12.21 Bn | 13.46% |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 4.97% |
| 5 | Pfizer | 158.80 Bn | 147.10 Bn | 10.94 Bn | -1.11% |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | 6.90% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 1.14% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | - |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 19.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.52% |
| Mar 31, 2026 | 30.25% |
| Dec 31, 2025 | 23.73% |
| Sep 30, 2025 | 55.88% |
| Jun 30, 2025 | 19.03% |
| Mar 31, 2025 | 14.89% |
| Dec 31, 2024 | 43.73% |
| Sep 30, 2024 | 17.79% |
| Jun 30, 2024 | 18.09% |
| Mar 31, 2024 | 19.71% |
| Dec 31, 2023 | 1.25% |
| Sep 30, 2023 | 38.07% |
| Jun 30, 2023 | 50.00% |
| Mar 31, 2023 | 42.53% |
| Dec 31, 2022 | 50.65% |
| Sep 30, 2022 | 62.45% |
| Jun 30, 2022 | 51.40% |
| Mar 31, 2022 | 54.82% |
| Dec 31, 2021 | 58.67% |
| Sep 30, 2021 | 60.65% |